About Affinivax
Affinivax is a Healthcare company based in Cambridge (United States) founded in 2013, and was acquired by GSK in May 2022. Technology-based conjugate vaccines against infectious diseases are developed. Affinivax has raised $359.49 million across 5 funding rounds from investors including BlackRock, Bain Capital and T. Rowe Price. The company has 132 employees. Its focus areas include Life Sciences, Immunotherapy, Vaccine and Therapeutic. Its legal entity is AFFINIVAX INC. Its competitors include Brii Biosciences, Insmed and Neon Therapeutics; 2 of its 3 listed competitors have raised funding.
Company details
Affinivax was established in 2013 in Cambridge, United States, within the biotechnology sector. Conjugate vaccines targeting infectious diseases are developed using the Multiple Antigen-Presenting System (MAPS) platform. Protective polysaccharides and proteins are conjugated into a single formulation through this technology. A broad immune response is elicited against pathogenic microorganisms. Operations center on advancing vaccine programs for various infectious threats.
- Headquarters Cambridge, United States
- Employees 132
- Stage Acquired
- SectorsHealthcare
- Website affinivax.com
- Social LinkedIn X
- Acquired by GSK (May 2022)
- Legal Name Affinivax Inc
Funding Insights of Affinivax
Affinivax has successfully raised a total of $359.49M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $226 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $359.49M
- Total Rounds 5
- Last Round Series C — $226M
- First Round $4M
(Oct 2014)
- Investors Count 15
All 5 funding rounds of Affinivax with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2021 | $226M | Series C | – | Rock Springs Capital, Foresite Capital | |
| Apr 2020 | $120M | Series B | – | Viking Global Investors | |
| Dec 2017 | $6.99M | Series A | – | – | – |
| Feb 2016 | $2.5M | Series A | – | Gates Foundation | – |
| Oct 2014 | $4M | Seed | – | Gates Foundation | – |
16 investors in total: 16 institutional.
Investors in Affinivax
Affinivax has secured backing from 16 investors, including venture fund and institutional investors. Prominent investors backing the company include BlackRock, Bain Capital and T. Rowe Price.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
Multi-stage investment firm invests in healthcare and life sciences companies | foresitecapital.com | New York, United States | ||
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Debt and equity investments are pursued across multiple sectors. | 1984 | baincapital.com | Boston, United States | |
Private investment firm focused on multiple sectors | vikingglobal.com | Greenwich, United States | ||
Private equity fund focused on the biotechnology sector | logoscapital.com | San Francisco, United States | ||
Diversified asset management services are provided to investors globally. | 1937 | troweprice.com | Baltimore, United States | |
Diversified investment management firm and private fund focused on debt, equity, and secondary market investments in multiple sectors | 1988 | blackrock.com | New York, United States | |
| ecor1cap.com | ||||
| logoscapital.io |
Investor details for Affinivax
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Affinivax
24 people are tracked at Affinivax (8 in leadership, 7 in board & advisors, 9 in team); the tracked headcount is 132.
| Name | Role | Group |
|---|---|---|
Ryan Burke | Director Supply Chain Planning | Leadership |
Jun Zhang | Director, Drug Product Formulation And Process Development | Leadership |
James Estrella | Associate Director Quality Assurance | Leadership |
Shite Sebastian | VP, Head of Product Development | Leadership |
Rick Malley | Chief Scientific Officer & Scientific Founder | Leadership |
Jayanthi Reddy | Vice President | Leadership |
Zvonko Ilic | Associate Director, Quality Assurance Validation | Leadership |
Onkar Sharma | Director | Leadership |
Bob More | Chairman | Board & advisors |
David Rossow | Director | Board & advisors |
Frances Heller | Director | Board & advisors |
Kris Jenner | Director | Board & advisors |
George Siber | Director | Board & advisors |
Steven Altschuler | Director | Board & advisors |
Andrew Hack | Director | Board & advisors |
Frank Malinoski | SVP, Clinical Development & Regulatory Affairs | Team |
Wajih Yazbek | Reseach Associate II | Team |
Kathryn Jordan | Senior Associate Scientist, In Vivo Sciences | Team |
Kaylee Verrington | QC Analyst 2 | Team |
Alex Barr | Associate Scientist | Team |
4 more people are available in the full profile.
Complete people profiles for Affinivax
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Affinivax
4 dated milestones of Affinivax across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Affinivax is founded.
- Funding First funding round of $4.0M.
- Funding Latest funding round, Series C, of $226.0M.
- Exit Acquired by GSK.
Competitors of Affinivax
Affinivax has 3 listed competitors in our database, 2 of them funded. They include Brii Biosciences, Insmed and Neon Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| briibio.com | 2018 | San Francisco, United States | $415M | 68 | Developer of biologics to treat hepatitis B infection | |
| insmed.com | 1999 | Bridgewater, United States | 912 | Developer of small molecule inhibitors for rare lung diseases | ||
| neontherapeutics.com | 2015 | Cambridge, United States | $161M | 306 | Tumor-specific neoantigens are identified for personalized cancer vaccine development. |
Detailed competitors of Affinivax
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Affinivax (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Affinivax
Complete news archive for Affinivax
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Affinivax
Affinivax was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Affinivax is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Affinivax is a funded company, having raised a total of $359.49M across 5 funding rounds to date. The company's 1st funding round was a Seed of $4M, raised on Oct 2014.
Affinivax has 132 employees.
Affinivax was established in 2013 in Cambridge, United States, within the biotechnology sector. Conjugate vaccines targeting infectious diseases are developed using the Multiple Antigen-Presenting System (MAPS) platform. Protective polysaccharides and proteins are conjugated into a single formulation through this technology. A broad immune response is elicited against pathogenic microorganisms. Operations center on advancing vaccine programs for various infectious threats.
Affinivax's top competitors include Brii Biosciences, Insmed and Neon Therapeutics.
Affinivax has 16 investors. Key investors include BlackRock, Bain Capital, T. Rowe Price, Citadel, and Gates Foundation.
Affinivax operates through Affinivax Inc.
Yes. Affinivax was acquired by GSK in May 2022.